Ethinyl Estradiol; Norelgestromin Patent Expiration

Ethinyl Estradiol; Norelgestromin is Used for preventing ovulation in women. It was first introduced by Janssen Pharmaceuticals Inc in its drug Ortho Evra on Nov 20, 2001. 5 different companies have introduced drugs containing Ethinyl Estradiol; Norelgestromin.


Ethinyl Estradiol; Norelgestromin Patents

Given below is the list of patents protecting Ethinyl Estradiol; Norelgestromin, along with the drug name that holds that patent and the company name owning that drug.

Filter patents by

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Ortho Evra US5876746 Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen Nov 20, 2015

(Expired)

Janssen Pharms
Ortho Evra US5972377 Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen Jun 07, 2015

(Expired)

Janssen Pharms



Ethinyl Estradiol; Norelgestromin's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Ethinyl Estradiol; Norelgestromin Generic API Manufacturers

Several generic applications have been filed for Ethinyl Estradiol; Norelgestromin. The first generic version for Ethinyl Estradiol; Norelgestromin was by Mylan Technologies Inc and was approved on Apr 16, 2014. And the latest generic version is by Zydus Pharmaceuticals Usa Inc and was approved on Sep 14, 2023.

Given below is the list of companies who have filed for Ethinyl Estradiol; Norelgestromin generic, along with the locations of their manufacturing plants worldwide.